United Therapeutics Receives FDA Clearance for Phase 1 Trial of Treprostinil-Iloprost SMI
United Therapeutics (UTHR) has received U.S. Food and Drug Administration (FDA) clearance to begin a Phase 1 open-label, single ascending dose study for its drug candidate, treprostinil-iloprost SMI. The clinical trial is designed to evaluate the safety, tolerability, and pharmacokinetics of the compound in healthy human subjects. The candidate is being developed as a potential treatment for pulmonary arterial hypertension (PAH). This milestone marks an early stage in the clinical development process for this specific combination therapy, which aims to address unmet needs within the PAH patient population.
Tickers: $UTHR
Topics: clinical trials drug development pulmonary arterial hypertension